Globally, multinational behemoths like Johnson & Johnson and Eli Lilly consistently rank as the wealthiest pharmaceutical enterprises by market capitalization and annual revenues. Driven by massive blockbuster portfolios spanning immunology, oncology, neuroscience, and medical devices, these corporate giants command multi-hundred-billion-dollar valuations that far exceed traditional peers.